foxo4-dri senolytic peptide human trials Frontiers (PDF) Senolytic Peptide FOXO4-DRI Selectively

Beyond wrinkle reduction, the broader body of GHK-Cu research shows: Skin thickness: A 2015 review in Biomedical Research International confirmed GHK-Cu's ability to increase skin density and thickness reversing the dermal thinning that characterizes photoaged skin Wound healing: Multiple studies confirm GHK-Cu accelerates wound healing by 3040% compared to untreated controls the same repair mechanism that drives anti-aging results Hair follicle activation: GHK-Cu extends the anagen (growth) phase of hair follicles and increases dermal papilla cell activity producing measurable increases in hair thickness and density Inflammation reduction: GHK-Cu consistently demonstrates anti-inflammatory effects, downregulating TNF- and other pro-inflammatory cytokines that drive skin aging and sensitivity Antioxidant activation: GHK-Cu upregulates the skin's own antioxidant defense systems, providing protection against UV-generated free radicals GHK-Cu reduced wrinkle volume by 55.8% compared to control and achieved a 31.6% greater reduction than Matrixyl 3000

For patients dealing with photodamage or hyperpigmentation, GHK-Cu reduces both by addressing the oxidative stress and inflammatory processes that drive them

They are not intended for human consumption, veterinary use, diagnosis, treatment, or performance enhancement.

Bottom line: Semaglutide is evidence-based